Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brugia malayi | 11 | 2015 | 39 | 1.940 |
Why?
|
| Filariasis | 7 | 2013 | 27 | 1.510 |
Why?
|
| Antigens, Helminth | 8 | 2014 | 190 | 1.510 |
Why?
|
| Murinae | 6 | 2014 | 10 | 0.950 |
Why?
|
| Elephantiasis, Filarial | 3 | 2013 | 13 | 0.860 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 2 | 2018 | 20 | 0.750 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2025 | 823 | 0.660 |
Why?
|
| Vaccines | 3 | 2013 | 369 | 0.660 |
Why?
|
| Immunoglobulin G | 5 | 2014 | 771 | 0.580 |
Why?
|
| Glioblastoma | 2 | 2018 | 333 | 0.580 |
Why?
|
| T-Lymphocytes | 8 | 2025 | 1696 | 0.570 |
Why?
|
| Vaccines, DNA | 2 | 2013 | 48 | 0.500 |
Why?
|
| Helminth Proteins | 2 | 2013 | 101 | 0.480 |
Why?
|
| Receptor, ErbB-2 | 4 | 2025 | 511 | 0.470 |
Why?
|
| Receptors, Histamine | 1 | 2013 | 3 | 0.430 |
Why?
|
| Histamine | 1 | 2013 | 44 | 0.420 |
Why?
|
| Biolistics | 1 | 2012 | 2 | 0.410 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 1241 | 0.410 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 162 | 0.400 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1393 | 0.390 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 18 | 0.380 |
Why?
|
| Immune Evasion | 1 | 2011 | 34 | 0.380 |
Why?
|
| Antibodies, Helminth | 6 | 2014 | 124 | 0.370 |
Why?
|
| Virulence Factors | 1 | 2011 | 173 | 0.340 |
Why?
|
| Vaccination | 2 | 2014 | 953 | 0.310 |
Why?
|
| Antigenic Variation | 2 | 2018 | 39 | 0.300 |
Why?
|
| Interferon-gamma | 4 | 2014 | 500 | 0.300 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 481 | 0.250 |
Why?
|
| Immunological Synapses | 1 | 2025 | 26 | 0.240 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 60 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 103 | 0.230 |
Why?
|
| Animals | 19 | 2025 | 34151 | 0.210 |
Why?
|
| Interleukin-4 | 2 | 2013 | 138 | 0.200 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2015 | 18 | 0.200 |
Why?
|
| Leishmania donovani | 2 | 2015 | 22 | 0.200 |
Why?
|
| Polyesters | 2 | 2013 | 40 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 3 | 2013 | 1003 | 0.190 |
Why?
|
| Sarcoma | 1 | 2024 | 195 | 0.190 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.170 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 95 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2021 | 185 | 0.170 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 176 | 0.160 |
Why?
|
| Ependymoma | 1 | 2020 | 134 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 327 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 177 | 0.150 |
Why?
|
| Gerbillinae | 3 | 2013 | 55 | 0.150 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 26 | 0.150 |
Why?
|
| Immunization | 3 | 2015 | 307 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 201 | 0.140 |
Why?
|
| Nitric Oxide | 4 | 2014 | 449 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2020 | 340 | 0.130 |
Why?
|
| Mice | 8 | 2025 | 17751 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 670 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2014 | 314 | 0.130 |
Why?
|
| Immunity, Humoral | 2 | 2013 | 69 | 0.130 |
Why?
|
| Cytokines | 4 | 2020 | 1273 | 0.130 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2302 | 0.120 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 202 | 0.120 |
Why?
|
| Enzyme Activators | 1 | 2014 | 10 | 0.120 |
Why?
|
| Larva | 2 | 2013 | 248 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 96 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1124 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 997 | 0.110 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 20 | 0.110 |
Why?
|
| Antibody Specificity | 1 | 2013 | 202 | 0.100 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 103 | 0.100 |
Why?
|
| Injections, Intradermal | 1 | 2012 | 31 | 0.100 |
Why?
|
| DNA, Helminth | 1 | 2012 | 22 | 0.100 |
Why?
|
| Immunity, Active | 1 | 2012 | 7 | 0.100 |
Why?
|
| Antibody Formation | 1 | 2013 | 262 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 887 | 0.100 |
Why?
|
| Spleen | 1 | 2013 | 280 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 3333 | 0.100 |
Why?
|
| COS Cells | 1 | 2012 | 276 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2012 | 113 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 262 | 0.100 |
Why?
|
| India | 1 | 2012 | 219 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 378 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2010 | 18 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 281 | 0.090 |
Why?
|
| Filaricides | 1 | 2010 | 4 | 0.090 |
Why?
|
| Flavanones | 1 | 2010 | 6 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2011 | 145 | 0.090 |
Why?
|
| Anthelmintics | 1 | 2010 | 55 | 0.090 |
Why?
|
| Helminths | 1 | 2010 | 46 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2010 | 52 | 0.090 |
Why?
|
| Hepatitis B Vaccines | 1 | 2010 | 41 | 0.080 |
Why?
|
| Flavonoids | 1 | 2010 | 78 | 0.080 |
Why?
|
| Helminthiasis | 1 | 2010 | 76 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2010 | 100 | 0.080 |
Why?
|
| Male | 11 | 2024 | 60883 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2009 | 187 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2009 | 154 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 686 | 0.070 |
Why?
|
| Humans | 12 | 2025 | 124263 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1064 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12264 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1414 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2025 | 78 | 0.060 |
Why?
|
| Vidarabine | 1 | 2024 | 79 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 109 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 119 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2014 | 43 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2013 | 46 | 0.050 |
Why?
|
| Microspheres | 2 | 2013 | 70 | 0.050 |
Why?
|
| Injections, Subcutaneous | 2 | 2013 | 126 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 421 | 0.050 |
Why?
|
| Particle Size | 2 | 2013 | 121 | 0.050 |
Why?
|
| Cricetinae | 2 | 2015 | 411 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 58 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 66 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 195 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 297 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 301 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 4351 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 289 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 185 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 336 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 568 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2020 | 325 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 392 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 747 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 661 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 382 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 285 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 285 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 571 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1241 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1478 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1742 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2015 | 71 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1570 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2015 | 126 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 60 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 392 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2415 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 120 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6087 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 4531 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 460 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1790 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 2974 | 0.020 |
Why?
|
| Rutin | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hesperidin | 1 | 2010 | 2 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2010 | 15 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 152 | 0.020 |
Why?
|
| Cations | 1 | 2010 | 39 | 0.020 |
Why?
|
| Emulsions | 1 | 2010 | 65 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2010 | 78 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 100 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 97 | 0.020 |
Why?
|
| Child | 2 | 2020 | 24476 | 0.020 |
Why?
|
| Female | 3 | 2024 | 66288 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 38 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 330 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 3057 | 0.020 |
Why?
|
| Proteome | 1 | 2009 | 239 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19386 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2008 | 406 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2006 | 101 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2008 | 376 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12460 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 26366 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14051 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 29355 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 6252 | 0.010 |
Why?
|